Global Metabolic Disorders Therapeutics Market 2016-2020

  • Published: Sep 2016
  • Pages: 163
  • SKU: IRTNTR10218

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

This market research report analyzes the leading players in the global metabolic disorders therapeutics market such as Novo Nordisk, Sanofi, Merck, AstraZeneca, and Eli Lily. This report also presents a detailed segmentation of the market by type of disease (diabetes drugs, obesity drugs, lysosomal storage disease drugs, and hypercholesterolemia drugs) and by geography (the Americas, APAC, and EMEA). 

Global metabolic disorders therapeutics market forecast

Extensive research carried out by the market research analysts at Technavio has shown that the global metabolic disorders therapeutics market will grow steadily and will post a moderate CAGR of close to 5% over the forecast period. The introduction of patient assistance programs for the treatment of various metabolic disorders is one of the primary factors driving this market’s growth. The leading vendors in the market are providing co-pay assistance to individuals who are purchasing the indicated medications for diabetes, hypercholesterolemia, obesity, and lysosomal storage diseases. Besides this, many organizations such as the National Gaucher Foundation of Canada, National Gaucher Foundation, and the National Organization for Rare Disorders are also involved in providing financial support to patients to continue with the therapy for rare diseases. Since such assistance programs are mostly provided by drug suppliers, patients show more inclination toward buying branded therapeutics, contributing to the metabolic disorders therapeutics market size in the coming years.

One of the upcoming trends gaining traction in the market is the increasing focus on oral insulin therapies. Till now, insulin injections were mostly administered through subcutaneous tissues, but this route of application is associated with risk of infection and hypersensitivity reactions, emboli, high cost, and injection site pain. Also, several needle-phobic individuals hesitate to adopt this route of administration. This paved the way for extensive research in the development of oral insulin. The oral form of insulin prevents the unpleasantness of insulin injections and other complications associated with the existing therapies. Moreover, oral administration of insulin ensures increased patient comfort and compliance, reduced risk of infection, simpler application, and is cost-effective.

Competitive landscape and key vendors

The global metabolic disorders therapeutics market is quite consolidated and dominated by the leading players such as Novo Nordisk and Sanofi. The increasing focus on R&D activities and investments by the market leaders ensure that product innovation is given priority. The vendors are competing to gain maximum metabolic disorders therapeutics market share.

Key vendors in this market are 

  • Novo Nordisk
  • Sanofi
  • Merck
  • AstraZeneca
  • Eli Lily

Other prominent vendors in the market include AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, nAmgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDm, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, NGM Biopharmaceuticals, Norgine BV, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix Biotherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, REGENX BioSciences, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Sanwa Kagaku Kenkyusho, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, SUN Pharma, Takeda, Teva, Thera technologies, Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, and Zydus Cadila.

Segmentation by type of disease and analysis of the metabolic disorders therapeutics market

  • Diabetes
  • Obesity
  • Hypercholesterolemia
  • Lysosomal storage diseases

According to this industry research report, the diabetes drugs segment was the leading segment and accounted for close to 64% of the revenue market shares. Depending on the cause, diabetes is essential of three types – type 1 diabetes, type 2 diabetes, and gestational diabetes. The increasing diabetic population globally is one of the significant factors propelling this market segment’s growth. According to various research studies, it is reported that at present nearly 415 million people are affected by diabetes globally, and this number is expected to increase to over 640 million by 2040.

Geographical segmentation and analysis of the metabolic disorders therapeutics market

  • Americas
  • APAC
  • EMEA

In terms of geography, the Americas was the highest revenue contributor in the global metabolic disorders therapeutics market and is likely to reach over USD 46 billion by 2020. The US is the largest revenue contributor in the region. The prevalence of diabetes is increasing at an alarming rate in the US, and various research studies have indicated that nearly half of the adult population in the country has diabetes, or they are at an elevated risk of developing diabetes. Moreover, the implementation of healthcare reforms such as the Affordable Care Act (ACA) is rapidly changing the business environment for pharmaceuticals. Healthcare reforms help reduce the cost of pharmaceutical drugs, offer increased access to healthcare, and improve the quality of healthcare. These healthcare reforms are anticipated to have a positive impact on the region’s market over the next four years.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global metabolic disorders therapeutics market?
  • What are the key market trends impacting the growth of the global metabolic disorders therapeutics market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global metabolic disorders therapeutics market?
  • What are the market opportunities and threats faced by the vendors in the global metabolic disorders therapeutics market?
  • What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
  • What are the key outcomes of the five forces analysis of the global metabolic disorders therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:


Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of  the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Pipeline portfolio

  • Pipeline portfolio: Global diabetes drugs market
  • Pipeline portfolio: Global hyperphosphatemia drugs market
  • Pipeline portfolio: Global anti-obesity drugs market

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation  by type of disease

  • Diabetes
  • Obesity
  • Hypercholesterolemia
  • Lysosomal storage diseases

PART 08: Global diabetes drugs market

  • Market overview
  • Global type 1 diabetes market
  • Global type 2 diabetes drugs market
  • Vendors in global diabetes drugs market

PART 09: Global hypercholesterolemia drugs market

  • Market overview
  • Vendors in global hypercholesterolemia drugs market

PART 10: Global lysosomal storage diseases market

  • Market overview
  • Vendors in global lysosomal storage disorders drugs market

PART 11: Global anti-obesity drugs market

  • Market overview
  • Vendors in global anti-obesity drugs market

PART 12: Geographical segmentation

  • Global metabolic disorders therapeutics market by geography 2015-2020
  • Metabolic disorders therapeutics market in Americas
  • Metabolic disorders therapeutics market in EMEA
  • Metabolic disorders therapeutics market in APAC

PART 13: Market drivers

  • Patient assistance programs
  • Special regulatory designations for rare diseases
  • Increase in academia-industry collaborations for drug development

PART 14: Impact of drivers

PART 15: Market challenges

  • Low compliance and adherence rates
  • High cost of therapies
  • Complex storage conditions and distribution policies for insulin

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Focus on oral insulin therapies
  • Strong and diversified pipeline portfolio
  • Strategic collaborations and acquisitions

PART 18: Vendor landscape

  • Competitive scenario
  • Other prominent vendors
  • PART 19: Key vendor analysis
  • Novo Nordisk
  • Sanof
  • Merck
  • AstraZeneca
  • Eli Lilly

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.


Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases


Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts



  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis


  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>